Protein stability effects in aggregate-based enzyme inhibition.

Small molecule aggregates are a leading cause of artifacts in early drug discovery, but little is known about their interactions with proteins, nor why some proteins are more susceptible to inhibition. A possible reason for this apparent selectivity is that aggregation-based inhibition, as a stoichiometric process, is sensitive to protein concentration, which varies across assays. Alternatively, local protein unfolding by aggregates may lead to selectivity, since stability varies among proteins. To deconvolute these effects, we used differentially stable point mutants of a single protein, TEM-1 β-lactamase. Broadly, destabilized mutants had higher affinities and were more inhibited to and by aggregates versus to more stable variants. Addition of the irreversible inhibitor moxalactam destabilized many mutants, and these typically bound with tighter to a colloidal particle, while mutant it stabilized bound weaker. These results suggest that less stable enzymes are more easily sequestered and inhibited by colloidal aggregates.

[1]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[2]  B K Shoichet,et al.  A relationship between protein stability and protein function. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Shoichet,et al.  A New Spin on Antibody-Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells. , 2017, ACS applied materials & interfaces.

[4]  B. Shoichet,et al.  Colloidal Drug Aggregate Stability in High Serum Conditions and Pharmacokinetic Consequence. , 2019, ACS chemical biology.

[5]  B. Shoichet,et al.  Functional analyses of AmpC β‐lactamase through differential stability , 1999 .

[6]  B. Shoichet,et al.  Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.

[7]  T. Kunkel Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Rajeevan Selvaratnam,et al.  Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators. , 2019, Journal of medicinal chemistry.

[9]  B. Shoichet,et al.  Interaction energies between β‐lactam antibiotics and E. coli penicillin‐binding protein 5 by reversible thermal denaturation , 2001, Protein science : a publication of the Protein Society.

[10]  B. Shoichet,et al.  Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture , 2012, ACS chemical biology.

[11]  John D. Chodera,et al.  Quantitative Self-Assembly Prediction Yields Targeted Nanomedicines , 2017, Nature Materials.

[12]  Functional analyses of AmpC beta-lactamase through differential stability. , 1999, Protein science : a publication of the Protein Society.

[13]  Brian K Shoichet,et al.  Colloidal aggregation: from screening nuisance to formulation nuance. , 2018, Nano today.

[14]  B. Shoichet,et al.  Noncovalent interaction energies in covalent complexes: TEM‐1 β‐lactamase and β‐lactams , 2002 .

[15]  D. Elnatan,et al.  Internal Structure and Preferential Protein Binding of Colloidal Aggregates. , 2017, ACS chemical biology.

[16]  B. Shoichet,et al.  Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams. , 2002, Proteins.

[17]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[18]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[19]  B. Shoichet,et al.  Stable Colloidal Drug Aggregates Catch and Release Active Enzymes. , 2016, ACS chemical biology.

[20]  Brian K Shoichet,et al.  A detergent-based assay for the detection of promiscuous inhibitors , 2006, Nature Protocols.

[21]  Maria F. Sassano,et al.  Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors , 2013, Journal of medicinal chemistry.

[22]  B. Shoichet,et al.  Colloidal aggregation and the in vitro activity of traditional Chinese medicines. , 2015, ACS chemical biology.

[23]  Paul J Lewi,et al.  Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. , 2005, Journal of medicinal chemistry.

[24]  John G. Quinn,et al.  Unlocking latent kinetic information from label-free binding , 2019, Scientific Reports.

[25]  Lynne S Taylor,et al.  Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs. , 2014, Journal of pharmaceutical sciences.

[26]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[27]  Kristin E. D. Coan,et al.  Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding , 2009, Journal of medicinal chemistry.

[28]  Christopher P Austin,et al.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.

[29]  B. Shoichet,et al.  Inhibition of AmpC beta-lactamase through a destabilizing interaction in the active site. , 2001, Biochemistry.

[30]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[31]  Brian K Shoichet,et al.  Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. , 2002, Journal of molecular biology.

[32]  Laurent Maveyraud,et al.  Structural Basis for Clinical Longevity of Carbapenem Antibiotics in the Face of Challenge by the Common Class A Beta-Lactamases from Antibiotic-Resistant Bacteria , 1998 .

[33]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[34]  Kristin E. D. Coan,et al.  Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. , 2008, Journal of the American Chemical Society.

[35]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[36]  C. Partch,et al.  Analysis of Protein Stability and Ligand Interactions by Thermal Shift Assay , 2015, Current protocols in protein science.

[37]  Kenneth M Merz,et al.  The Ecstasy and Agony of Assay Interference Compounds. , 2017, Journal of medicinal chemistry.